Oxford: Novo Nordisk Pharma’s leading weight loss drug Ozempic has also been linked to a lower risk of dementia and other mental illnesses in a recent study.
In a study conducted by experts at Oxford University, people who took Ozampic had a 48% lower risk of dementia after one year than those who took sitagliptin, an older drug. In addition, the risk of cognitive decline in such individuals was also lower compared to those taking sitagliptin.
The researchers published the findings in The Lancet e-Clinical Medicine journal. It also found that people taking Ozampic had a 28 percent lower risk of smoking than those taking the drug glipizide.
It should be noted that this study provides valuable insight into the potential benefits of semaglutide, the main ingredient in Ozempic and Vigovi, in addition to diabetes control and weight loss.